StockMarketWire.com - Benchmark, the aquaculture health, nutrition, and genetics business, has announced the results of its highly successful first commercial scale field trial of its next generation sea lice treatment in Norway.

The group said that in this first field trial, its total treatment solution showed 100% efficacy and no environmental impact due to its proprietary purification system, CleanTreat, which removes any detectable traces of medicine from treatment water before it is discharged into the ocean.

It said field trials would continue as part of regulatory process.

The company said: 'Together, Ectosan and CleanTreat are a ground breaking development for the salmon industry, as sea lice is one of the industry's biggest disease challenges.

'In 2016 sea lice infestation resulted in a 5% contraction in the production of salmon in Norway, equivalent to 70,000 tons or an estimated $500m at current market prices (Source: Rabobank).

'There is a recognised lack of effective, environmentally and welfare friendly solutions in the market, and Ectosan and CleanTreat have the potential to address this need.'

The company believes that Ectosan can achieve worldwide peak sales of £40-50m.


At 9:07am: [LON:BMK] Benchmark Holdings Plc share price was +2.5p at 55.5p



Story provided by StockMarketWire.com